Browsing Tag
PYC Therapeutics Ltd
1 post
Can PYC Therapeutics (ASX: PYC) turn clean safety data into investor confidence as ADOA trial expands?
PYC Therapeutics advances its RNA-based ADOA drug PYC-001 into a global Phase 1/2 multi-dose trial after a successful safety review. Find out what it means for biotech investors and patients.